KRAS and breast carcinoma: For example, integrative studies in breast cancer have shown that PIK3CA mutations correlate with specific transcriptional programs [74], and similar mutation–expression relationships have been identified for EGFR and KRAS in lung adenocarcinoma [73] and for IDH1 and TP53 in glioblastoma [72,73,74].